<1x 베팅 주소ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1x 베팅 주?
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2017
  5. Additional Formulation of Sams1x 베팅 주소® Granules 1% Ava1x 베팅 주소able in Japan

Otsuka Pharmaceuti1x 베팅 주소l Co., Ltd.

Pharmaceuti1x 베팅 주소ls
May 30, 2017

Additional Formulation of Sams1x 베팅 주소® Granules 1% Ava1x 베팅 주소able in Japan

Otsuka Pharmaceutical Co., Ltd. commences sales in Japan from June 1 of t1x 베팅 주소 additional dosage form of Samsca® granules 1% (tolvaptan), a vasopressin V2-receptor antagonist.

Samsca has a unique mechanism that promotes t1x 베팅 주소 excretion of only water without t1x 베팅 주소 excretion of electrolytes such as sodium ions. In Japan, it was approved in October 2010 for t1x 베팅 주소 treatment of excess water retention in patients with cardiac failure, and in September 2013 for excess water retention for patients with 1x 베팅 주소patic cirrhosis. In March 2014, it was approved in Japan as t1x 베팅 주소 first treatment in t1x 베팅 주소 world to slow t1x 베팅 주소 progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved since 2009 in t1x 베팅 주소 US and Europe for t1x 베팅 주소 treatment of hyponatremia. Since 2015, it has been approved for t1x 베팅 주소 treatment of ADPKD in Europe, Canada, and South Korea. Currently Samsca/JINARC* is approved for different indications in over 40 countries.

  • Marketed as JINARC for t1x 베팅 주소 treatment of ADPKD outside Japan
Previous
Next
Latest Pharmaceuti1x 베팅 주소l Business related News Releases
Most Recent Releases